7 results about "Alpha amino acid" patented technology

The invention relates to a method of manufacturing a peptide P, which comprises a step of condensing of an alpha amino acid derivative S-am, which has one unprotected alpha amino group or one unprotected alpha imino group, with a protected alpha amino acid derivative of formula (Pr-L), wherein the amino protecting group RL-N-1 is 1,1-dioxobenzo[b]thiophen-2-ylmethyloxycarbonyl (Bsmoc). The invention relates also to a method of manufacturing the alpha amino acid derivative of formula (Pr-L) and an involved lysine derivative with its alpha amino group being protected by 1,1-dioxobenzo[b]thiophen-2-ylmethyloxycarbonyl (Bsmoc).

Provided are: an anticancer agent having excellent cell membrane permeability; and a pharmaceutical composition containing the anticancer agent. Namely, the present invention provides an anticancer agent having, as an active ingredient, a fluorine-containing amino acid in which one or more hydrogen atoms bonded to a carbon atom of an alpha amino acid are substituted with a fluorine atom, or a pharmacologically acceptable salt thereof, the fluorine-containing amino acid having a monofluoromethyl group, a difluoromethyl group, or a trifluoromethyl group. And a pharmaceutical composition containing any one of these.

A method of forming a non-canonical amino acid (ncAA) includes utilizing a substrate, an amino acid, an enzyme, actinic radiation, a photocatalyst, and an oxidant to form a non- canonical amino acid, wherein the enzyme includes one or more pyridoxal phosphate (PLP)- dependent enzymes or variants thereof. A method of forming a non-canonical amino acid (ncAA) includes utilizing an organoboron compound, an alpha amino acid, an enzyme, a photocatalyst, and an oxidant to form a sp3-sp3 coupled non-canonical amino acid product, wherein the oxidant includes at least one of a manganese-containing compound, an iron- containing compound, and a copper-containing compound.

The present disclosure pertains to iodinated poly (amino acid) compounds that comprise residues of alpha amino acids that comprise an alpha carboxyl group, an alpha amino group, and a primary-amine-containing side chain comprising an amino group. The poly(amino acid) compounds comprise amide linkages formed from the alpha carboxyl groups and the amino groups of the primary-amine-containing side chains of the alpha amino acids forming the iodinated poly(amino acid) compound, at least one of the residues of the alpha amino acids in the iodinated poly(amino acid) compound is covalently modified to include one or more iodine atoms, and at least two of the alpha amino acid residues in the iodinated poly(amino acid) compound are not covalently modified. The present disclosure also provides crosslinked radiopaque hydrogels formed from such iodinated poly(amino acid) compounds, methods of treatment using such iodinated poly(amino acid) compounds, and systems containing such iodinated poly(amino acid) compounds.

Provided herein are perfusate compositions, and methods and systems for using such composition to perfuse a vascularized composite tissue (e.g., limb, face, abdominal wall or flap) to preserve such composite tissues (e.g., for auto or allotransplant). In certain embodiments, the perfusate compositions comprise at least one of the following reagents: i) N-acetylcysteine; ii) pantothenate or pantothenic acid at a concentration of at least 15 micromol / liter in said composition; and / or iii) carnitine, as well as further comprising one of the following: i) at least one bicarbonate / CO2-dependent anaplerotic substrate, and at least one bicarbonate / CO2 buffer, or ii) at least one non-bicarbonate / CO2-dependent anaplerotic substrate. In certain embodiments, the perfusate compositions are free, or detectably free, of alpha amino acids.

The invention relates to a cross-linked dextran polymer Dx bearing anionic groups in which the at least divalent group L (-) i is covalently bound to the main chain of a dextran polymer having i-W-groups, where-L (-) i is a linear or branched polyether or a linear or branched poly (# imgabs0 # oxazoline), -i is the valence of L and the number of-W-groups bound to the dextran polymer and is an integer of 2 to 8 (2 < = i < = 8)--W-is a group comprising at least one linear or branched alkyl group and optionally comprising a heteroatom such as oxygen, nitrogen or sulfur, an aromatic ring, a polyether derivative or a poly (# imgabs 1 # oxazoline) derivative, and which does not comprise two or more alpha amino acid residues, in particular alpha amino acid residues linked by peptide linkages. The invention also relates to a dextran polymer prior to the cross-linking reaction and to a method for synthesizing the cross-linked dextran polymer according to the invention into a hydrogel form. The invention also relates to hydrogels comprising the cross-linked dextran polymer of the invention and / or to hydrogels further comprising biological cells. The invention also relates to the therapeutic use of the hydrogel according to the invention for the treatment of a condition or disease in a mammal, wherein the condition or disease is caused by an endocrine deficiency or dysfunction of the pancreatic organ, and to an implant comprising the hydrogel according to the invention.

A method of forming a non-canonical amino acid (ncAA) includes utilizing a substrate, an amino acid, an enzyme, actinic radiation, a photocatalyst, and an oxidant to form a non- canonical amino acid, wherein the enzyme includes one or more pyridoxal phosphate (PLP)- dependent enzymes or variants thereof. A method of forming a non-canonical amino acid (ncAA) includes utilizing an organoboron compound, an alpha amino acid, an enzyme, a photocatalyst, and an oxidant to form a sp3-sp3 coupled non-canonical amino acid product, wherein the oxidant includes at least one of a manganese-containing compound, an iron- containing compound, and a copper-containing compound.